Search

Displaying results 8561 - 8570 of 10000 in total
  1. Drug

    BN‐Brachyury vaccine

    go.drugbank.com/drugs/DB17425
    Experimental

    It is composed of the [MVA-BN-brachyury-TRICOM vaccine] and the fowlpox virus(FPV)‐Brachyury booster vaccine.[A255173]

  2. Drug

    Phelimin

    go.drugbank.com/drugs/DB18332
    Experimental

    Phelemin (PHE-MIP) is a methacrylic acid-based copolymer purified to bind to L-phenylalanine and L-phenylalanine-containing peptides.

  3. Drug

    Modakafusp alfa

    go.drugbank.com/drugs/DB16399
    Investigational

    Modakafusp alfa is under investigation in clinical trial NCT03215030 (A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory

  4. Drug

    Suvecaltamide

    go.drugbank.com/drugs/DB19139
    Investigational

    Suvecaltamide is under investigation in clinical trial NCT05122650 (A Study to Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)).

  5. Drug

    Mevonlerbart

    go.drugbank.com/drugs/DB19416
    Investigational

    Mevonlerbart is under investigation in clinical trial NCT06602726 (A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy

  6. Drug

    MEDI-6469

    go.drugbank.com/drugs/DB15306
    Investigational

    MEDI-6469 is a monoclonal antibody under investigation in clinical trial NCT02205333 (A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies

  7. Drug

    Edotecarin

    go.drugbank.com/drugs/DB04882
    Investigational

    Edotecarin is a novel, non-camptothecin, DNA topoisomerase I inhibitor. It is member of the class of compounds called indolocarbazoles.

  8. Drug

    AGS-005

    go.drugbank.com/drugs/DB05741
    Experimental

    AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's

  9. Drug

    Biropepimut-S

    go.drugbank.com/drugs/DB14816
    Investigational

    Biropepimut-S is under investigation in clinical trial NCT02873819 (Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral

  10. Drug

    Ilacirnon

    go.drugbank.com/drugs/DB16066
    Investigational

    Ilacirnon (CCX-140) is under investigation in clinical trial NCT01440257 (A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria).